Domestic Pharma Drives JNJ's 1Q; Stock Hits All-Time High
publication date: Apr 19, 2016
Johnson & Johnson reported strong growth in its Pharmaceutical segment in the first quarter of 2016. The underlying strength allowed the firm to raise its full-year forecasts after adjusting its outlook on currency expectations for the year.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!